BRPI0518328A2 - agente de contraste, composiÇço farmacÊutica, uso de um agente de contraste, mÉtodo para gerar imagens realÇadas de um corpo animal ou humano, e, kit para a preparaÇço de um composiÇço radiofarmacÊutica - Google Patents

agente de contraste, composiÇço farmacÊutica, uso de um agente de contraste, mÉtodo para gerar imagens realÇadas de um corpo animal ou humano, e, kit para a preparaÇço de um composiÇço radiofarmacÊutica

Info

Publication number
BRPI0518328A2
BRPI0518328A2 BRPI0518328-6A BRPI0518328A BRPI0518328A2 BR PI0518328 A2 BRPI0518328 A2 BR PI0518328A2 BR PI0518328 A BRPI0518328 A BR PI0518328A BR PI0518328 A2 BRPI0518328 A2 BR PI0518328A2
Authority
BR
Brazil
Prior art keywords
contrast agent
animal
kit
preparation
human body
Prior art date
Application number
BRPI0518328-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Dagfinn Lovhaug
Morten Eriksen
Hege B Fjerdingstad
Andrew Healey
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of BRPI0518328A2 publication Critical patent/BRPI0518328A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Steroid Compounds (AREA)
BRPI0518328-6A 2004-11-22 2005-11-21 agente de contraste, composiÇço farmacÊutica, uso de um agente de contraste, mÉtodo para gerar imagens realÇadas de um corpo animal ou humano, e, kit para a preparaÇço de um composiÇço radiofarmacÊutica BRPI0518328A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20045081 2004-11-22
PCT/NO2005/000435 WO2006054904A2 (en) 2004-11-22 2005-11-21 Contrast agents to target extracellular matrix

Publications (1)

Publication Number Publication Date
BRPI0518328A2 true BRPI0518328A2 (pt) 2008-11-11

Family

ID=36182407

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518328-6A BRPI0518328A2 (pt) 2004-11-22 2005-11-21 agente de contraste, composiÇço farmacÊutica, uso de um agente de contraste, mÉtodo para gerar imagens realÇadas de um corpo animal ou humano, e, kit para a preparaÇço de um composiÇço radiofarmacÊutica

Country Status (17)

Country Link
US (1) US8182790B2 (enExample)
EP (2) EP2243496A3 (enExample)
JP (2) JP5116480B2 (enExample)
KR (1) KR20070091609A (enExample)
CN (1) CN101107016B (enExample)
AT (1) ATE494913T1 (enExample)
AU (1) AU2005307195A1 (enExample)
BR (1) BRPI0518328A2 (enExample)
CA (1) CA2586621A1 (enExample)
DE (1) DE602005025911D1 (enExample)
ES (1) ES2358745T3 (enExample)
IL (1) IL182898A0 (enExample)
MX (1) MX2007006050A (enExample)
NO (1) NO20073039L (enExample)
RU (1) RU2007118385A (enExample)
WO (1) WO2006054904A2 (enExample)
ZA (1) ZA200705043B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
CN101528270A (zh) * 2006-08-28 2009-09-09 通用电气健康护理有限公司 基于68Ga标记的肽的放射性药物
JP2008266194A (ja) * 2007-04-19 2008-11-06 Hiroshi Tanaka 分子プローブの原料として有用な新規有機化合物
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
JP5604305B2 (ja) * 2007-12-13 2014-10-08 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 線維症の非侵襲性の特異的イメージングのための、ポリペプチド、環状ポリペプチドおよびそれを含む医薬
EP2244741B1 (en) 2008-01-18 2015-03-25 VisEn Medical, Inc. Fluorescent imaging agents
AU2009246397B2 (en) 2008-05-13 2013-01-17 University Of Kansas Metal abstraction peptide (MAP) tag and associated methods
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
KR100991716B1 (ko) * 2009-10-22 2010-11-04 경북대학교 산학협력단 광학영상 조영제, 그 용도 및 장치
CN102504603B (zh) * 2011-10-20 2014-01-29 中国海洋大学 一种多聚物与生物染色剂的偶合物及其制备方法和用途
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
US20170050989A1 (en) * 2013-12-03 2017-02-23 The General Hospital Corporation Molecular Imaging Probes
CN117623996B (zh) * 2022-08-10 2025-07-22 中国药科大学 一种二价keap1-nrf2抑制剂、制备方法及其医药用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4615876A (en) * 1983-04-25 1986-10-07 Curators Of The University Of Missouri Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US6048982A (en) 1986-04-18 2000-04-11 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
DE68927479T2 (de) 1988-05-02 1997-04-03 Phanos Tech Inc Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
GB8903022D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
CA2124329C (en) 1991-11-27 2008-11-18 Gregory A. Kopia Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
ATE314097T1 (de) * 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
CA2269985A1 (en) 1996-10-28 1998-05-07 Aslak Godal Improvements in or relating to diagnostic/therapeutic agents
AU5871798A (en) * 1997-01-29 1998-08-18 Nycomed Imaging As Polymers
US6348599B1 (en) 1997-07-28 2002-02-19 Nycomed Amersham Plc Cyanine dyes
US5942637A (en) * 1998-03-30 1999-08-24 North Dakota State University Research Foundation Compounds containing tetradecachlorocyclohexasilane dianion
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
WO1999058139A2 (en) * 1998-05-08 1999-11-18 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
US6230777B1 (en) 1999-02-04 2001-05-15 Midmac Systems, Inc. Filter forming and joining apparatus
JP5043271B2 (ja) * 2000-04-12 2012-10-10 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチドベースの化合物
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
EP1337278A2 (en) 2000-11-27 2003-08-27 Bristol-Myers Squibb Medical Imaging, Inc. Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
GB0116815D0 (en) 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
CN1622830A (zh) * 2001-07-10 2005-06-01 安盛药业有限公司 肽基化合物
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
JP2006510576A (ja) 2002-06-17 2006-03-30 カルテラ、アクチボラグ アテローム性動脈硬化症のプラーク形成の進行を防止するためのインテグリンα１０鎖の方法および使用
US7063158B2 (en) 2003-06-16 2006-06-20 Deepwater Technologies, Inc. Bottom tensioned offshore oil well production riser
NO20033115D0 (no) 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
GB0317815D0 (en) * 2003-07-30 2003-09-03 Amersham Health As Imaging agents
WO2005019247A2 (en) * 2003-08-15 2005-03-03 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
US7431914B2 (en) * 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
CN1925876A (zh) * 2004-03-04 2007-03-07 通用电气医疗集团股份有限公司 用于诊断和治疗的血管紧张素肽类似物和螯合剂的缀合物
RU2393167C2 (ru) * 2004-06-16 2010-06-27 Джи-И Хелткер АС Пептидные соединения
AU2005254915B2 (en) 2004-06-16 2011-10-13 Ge Healthcare As Peptide-based compounds

Also Published As

Publication number Publication date
JP5116480B2 (ja) 2013-01-09
AU2005307195A1 (en) 2006-05-26
CA2586621A1 (en) 2006-05-26
DE602005025911D1 (de) 2011-02-24
NO20073039L (no) 2007-08-16
JP2012207027A (ja) 2012-10-25
IL182898A0 (en) 2007-08-19
ATE494913T1 (de) 2011-01-15
EP1814598B1 (en) 2011-01-12
EP1814598A2 (en) 2007-08-08
JP2008520658A (ja) 2008-06-19
EP2243496A3 (en) 2012-12-26
KR20070091609A (ko) 2007-09-11
ZA200705043B (en) 2008-09-25
US8182790B2 (en) 2012-05-22
ES2358745T3 (es) 2011-05-13
CN101107016A (zh) 2008-01-16
MX2007006050A (es) 2007-11-14
WO2006054904A2 (en) 2006-05-26
WO2006054904A3 (en) 2007-04-05
EP2243496A2 (en) 2010-10-27
CN101107016B (zh) 2011-11-16
US20090208412A1 (en) 2009-08-20
RU2007118385A (ru) 2008-12-27

Similar Documents

Publication Publication Date Title
BRPI0408236A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
ZA200705043B (en) Contrast agents to target extracellular matrix
BRPI0210886B8 (pt) composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
BRPI0111220B1 (pt) conjugados de fármacos com etilenodicisteína (ec)
UA103758C2 (ru) Конъюгаты олигомеров инсулина, их композиции и применение
WO2001082975A3 (en) Membrane-permeant peptide complexes for medical imaging
BRPI0316532B8 (pt) composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável
BRPI0507684A (pt) agentes de contraste para formação de imagem de perfusão miocárdica
YU72901A (sh) Preparati za primenu u terapiji i dijagnozi raka pluća
BR0313197A (pt) Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
TW200616661A (en) HER2 antibody composition
BRPI0510274B8 (pt) uso de um agente para tratar ou prevenir doença celíaca, composição farmacêutica compreendendo dito agente, método de diagnóstico de doença celíaca, ou suscetibilidade à doença celíaca, uso do dito agente para a preparação de um meio de diagnóstico e kit para realizar o dito método de diagnóstico
BRPI0416528A (pt) agente de formação de imagem, composição farmacêutica, composição radiofarmacêutica, conjugado, kit para a preparação da composição radiofarmacêutica, e, uso do agente de formação de imagem
BR0003987A (pt) Composição laxativa
BRPI0507824A (pt) hidroxiapatita, processo para a preparação de um particulado de hidroxiapatita marcada com radionuclìdeo, composição farmacêutica, uso de hidroxiapatita e de um radionuclìdeo emissor de alfa ou um radionuclìdeo emissor de beta, dispositivo, e, método de tratamento radioquìmico de um ser humano ou de um indivìduo animal não humano necessitando do mesmo
BRPI0416938A (pt) agente de formação de imagem, composição, conjugado, kit para a preparação da composição radiofarmacêutica
BR0215148A (pt) Composições farmacêuticas de agonista parcial 5ht4
BRPI0415713A (pt) mio-inositol hexafosfato para uso tópico
MXPA03004499A (es) Kit de repinotan.
NO20034504D0 (no) Erytropoietin forbedrer in vivo kjemoterapiindusert toksisitet
WO2004100998A3 (en) Compositions and methods for non-invasive imaging of soluble beta-amyloid
AU9363398A (en) Hepatitis c receptor protein cd81
BRPI0412453A (pt) uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo
BRPI0515894A (pt) agente de formação de imagem, composições farmacêutica e radiofarmacêutica, conjugado de um inibidor de metaloproteinase matricial com um ligando, precursor para a preparação da composição radiofarmacêutica, kit para a preparação da composição radiofarmacêutica, e, uso do agente de formação de imagem
CA2069638A1 (en) Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]